Literature DB >> 20489539

Evisceration with equatorial sclerotomy for phthisis bulbi and microphthalmos.

Dan Georgescu1, M Reza Vagefi, Chun Cheng Lin Yang, John McCann, Richard L Anderson.   

Abstract

PURPOSE: To describe a new technique for ocular volume augmentation at the time of evisceration in patients with phthisis bulbi and microphthalmos.
METHODS: A retrospective, interventional, noncomparative case series of all patients with phthisis bulbi and microphthalmos who underwent successful evisceration with equatorial sclerotomy. The medical records were reviewed for patient history, surgical method, and postoperative course.
RESULTS: Eighteen patients (16 with phthisis bulbi and 2 with microphthalmos) underwent evisceration with equatorial sclerotomy and placement of an orbital implant of 20 mm in 11 patients (61%), 18 mm in 6 patients (33%) and 16 mm in 1 patient. Complications encountered were implant exposure in one patient, fornix shortening and symblepharon in one patient, and enophthalmos in another.
CONCLUSION: Equatorial sclerotomy could be a useful adjuvant technique for placement of a larger orbital implant at the time of evisceration in patients with phthisis bulbi and microphthalmos.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20489539     DOI: 10.1097/IOP.0b013e3181b8c895

Source DB:  PubMed          Journal:  Ophthalmic Plast Reconstr Surg        ISSN: 0740-9303            Impact factor:   1.746


  3 in total

1.  Combined retro-peribulbar and subconjunctival anesthesia for evisceration surgery.

Authors:  Bulent Yazici; Ceren Poroy; Ugur Yayla
Journal:  Int Ophthalmol       Date:  2019-07-13       Impact factor: 2.031

2.  Autologous sclera-muscle flaps technique in evisceration with hydroxyapatite implantation.

Authors:  Ying Zhu; Hong Zhang; Yin-Wei Song; Jing-Min Guo; Xiao-Lan Xu; Jun-Ming Wang
Journal:  Int J Ophthalmol       Date:  2015-08-18       Impact factor: 1.779

3.  Evisceration in the modern age.

Authors:  Laura T Phan; Thomas N Hwang; Timothy J McCulley
Journal:  Middle East Afr J Ophthalmol       Date:  2012-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.